{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:28Z","timestamp":1793293888079,"version":"4.5.0"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia (IP) in patients with polymyositis (PM) and dermatomyositis (DM). Postmarketing surveillance was initiated to examine long-term outcomes of immunosuppressive regimens containing tacrolimus in real-world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Observational, prospective, postmarketing surveillance is ongoing in 179 patients with PM\/DM-associated IP initiating treatment with tacrolimus. We report interim findings after 2 years of follow-up. Cumulative overall survival was assessed using Kaplan-Meier analysis. Potential prognostic factors for mortality were assessed by univariate Cox proportional hazards analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 170 patients were included in this analysis. At the time of starting treatment with tacrolimus, almost all patients were receiving corticosteroids (98.8%), and cyclophosphamide was additionally used in 42 patients (24.7%). Forty-nine patients (28.8%) discontinued tacrolimus during follow-up, mainly due to loss to follow-up, patient death, and adverse events. Mean (SD) oral corticosteroid dose decreased from 32.4 (21.6) mg\/day at baseline to 7.6 (4.2) mg\/day at 2 years. Overall survival at 2 years was 90.3%; corresponding progression-free survival was 62.5%. Factors found to be associated with all-cause mortality included diagnosis of clinically amyopathic DM (hazard ratio [HR] 9.04, 95% CI 1.18-69.51 vs PM), ferritin level 500 to &lt; 1500 ng\/mL (HR 8.61, 95% CI 2.51-29.45 vs &lt; 500 ng\/mL), and presence of antimelanoma differentiation-associated gene 5 antibodies (HR 8.16, 95% CI 1.03\u201364.47 vs absence).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Immunosuppressive regimens containing tacrolimus appear useful for the management of IP in patients with PM\/DM. [ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02159651\">NCT02159651<\/jats:ext-link>]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.210322","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T12:25:23Z","timestamp":1650025523000},"page":"707-718","source":"Crossref","is-referenced-by-count":11,"title":["Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan"],"prefix":"10.3899","volume":"49","author":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Wakasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022070105203838000_49.7.707.1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"2022070105203838000_49.7.707.2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371528"},{"key":"2022070105203838000_49.7.707.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.30513"},{"key":"2022070105203838000_49.7.707.4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"2022070105203838000_49.7.707.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01933.x"},{"key":"2022070105203838000_49.7.707.6","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124023"},{"key":"2022070105203838000_49.7.707.7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314554849"},{"key":"2022070105203838000_49.7.707.8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology"},{"key":"2022070105203838000_49.7.707.9","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/1756-185X.12931","article-title":"Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis","volume":"19","author":"Ueno","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2022070105203838000_49.7.707.10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2015.12.004","article-title":"Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease","volume":"36","author":"Witt","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"2022070105203838000_49.7.707.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161217"},{"key":"2022070105203838000_49.7.707.12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1756-185X.13414","article-title":"Efficacy and safety of oral high-trough level tacrolimus in acute\/subacute interstitial pneumonia with dermatomyositis","volume":"22","author":"Suzuka","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2022070105203838000_49.7.707.13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"key":"2022070105203838000_49.7.707.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2022070105203838000_49.7.707.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2022070105203838000_49.7.707.16","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120621"},{"key":"2022070105203838000_49.7.707.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.04.007"},{"key":"2022070105203838000_49.7.707.18","first-page":"254","article-title":"Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis","volume":"35","author":"Kotani","year":"2008","journal-title":"J Rheumatol"},{"key":"2022070105203838000_49.7.707.19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"key":"2022070105203838000_49.7.707.20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085062"},{"key":"2022070105203838000_49.7.707.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621"},{"key":"2022070105203838000_49.7.707.22","doi-asserted-by":"crossref","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"2022070105203838000_49.7.707.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"key":"2022070105203838000_49.7.707.24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"JAMI investigators. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"2022070105203838000_49.7.707.25","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1029239"},{"key":"2022070105203838000_49.7.707.26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/14397595.2017.1332471","article-title":"Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): post-marketing surveillance in Japan","volume":"28","author":"Takeuchi","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2022070105203838000_49.7.707.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191008"},{"key":"2022070105203838000_49.7.707.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22728"},{"key":"2022070105203838000_49.7.707.29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2022070105203838000_49.7.707.30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrrheum.2016.120","article-title":"Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis","volume":"12","author":"Gono","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2022070105203838000_49.7.707.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.01.014"},{"key":"2022070105203838000_49.7.707.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098824"},{"key":"2022070105203838000_49.7.707.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:23:08Z","timestamp":1656678188000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,1]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.3899\/jrheum.210322"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210322","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}